Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:address |
gptkb:31_East_62nd_Street,_New_York,_NY_10065,_USA
|
| gptkbp:CEO |
gptkb:Phillip_L._Gomez
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
infectious diseases
antiviral treatments |
| gptkbp:founded |
1995
|
| gptkbp:headquartersLocation |
gptkb:New_York_City
|
| https://www.w3.org/2000/01/rdf-schema#label |
SIGA Technologies Inc.
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:notable_contract |
U.S. government procurement of TPOXX
|
| gptkbp:notableFor |
smallpox treatment
|
| gptkbp:numberOfEmployees |
approximately 40 (2023)
|
| gptkbp:product |
gptkb:TPOXX
gptkb:tecovirimat |
| gptkbp:publiclyTraded |
true
|
| gptkbp:stockSymbol |
gptkb:SIGA
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.siga.com/
|
| gptkbp:bfsParent |
gptkb:MacAndrews_&_Forbes_Incorporated
|
| gptkbp:bfsLayer |
7
|